Biopharmas Escape 'Death Panel,' But 2017 Lurks
Executive Summary
Investors drove shares of biopharmaceutical companies up on June 22 on the news the projected growth rate in Medicare spending did not exceed the threshold needed this year to trigger the so-called Independent Payment Advisory Board (IPAB) to make recommendations for curbing spending. Republicans are opposed to the IPAB, calling it an "unelected and unaccountable board of bureaucrats," with some even dubbing it a "death panel."
You may also be interested in...
Divide Runs Deep Over Medicare B Drug Payment Experiment
A May 17 hearing examining the Obama administration's proposed plan to test alternative payment methods for drugs covered under Medicare Part B highlighted the deep divide that exists not only between Republicans and Democrats, but within the latter party itself. The Centers for Medicare & Medicaid Services, which proposed the experiment, wasn't invited to the hearing.
PhRMA Condemns Medicare B Rx Drug Payment Experiment
The Pharmaceutical Researchers and Manufacturers of America (PhRMA) wasted no time in condemning the Obama administration's plans to launch a new experiment testing whether alternative payment designs may lead to reducing Medicare Part B expenditures, while preserving and potentially even enhancing beneficiaries' quality of care.
HHS: ACA saved seniors $11.5bn on Rx drugs
The deal the White House and Democrats struck with the biopharmaceutical industry to close the so-called donut hole in the Medicare Part D prescription drug plan under the Affordable Care Act (ACA) and rebates led to 8.2 million seniors and Americans with disabilities saving $11.5bn since 2010 – an average savings of $1,407, according to a new report from Health and Human Services.